Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo
Blood Advances · 2023
DOI: 10.1182/bloodadvances.2023010643 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Advances, 2023. Verfasst von Yvonne K Jongejan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden Universit…. Hauptthemen laut MEDLINE: von Willebrand Factor, RNA, Small Interfering, Alleles, Gene Silencing. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
An imbalance in von Willebrand factor (VWF) may either lead to bleeding (von Willebrand disease, VWD) or thrombosis. Both disorders have shortcomings in the currently available treatments. VWF itself could be a potential therapeutic target because of its role in both bleeding and thrombosis. Inhibiting VWF gene expression through allele-selective silencing of VWF with small interfering RNAs (siRNAs) could be a personalized approach to specifically inhibit mutant VWF in VWD or to normalize increased VWF levels in thrombotic disorders without complete VWF knockdown. Therefore, we investigated a method to allele-selectively silence the VWF gene in mice as a therapeutic strategy. Fourteen candidate siRNAs targeting murine Vwf of either the C57BL/6J (B6) or the 129S1/SvImJ (129S) strain were tested in vitro in cells expressing B6- and 129S-Vwf for inhibitory effect and allele-selective potential. Together with a nonselective siVwf, 2 lead candidate siRNAs, siVwf.B6 and siVwf.129S, were further tested in vivo in B6 and 129S mice. Efficient endothelial siRNA delivery was achieved by siRNA encapsulation into 7C1 oligomeric lipid nanoparticles. Treatment with the nonselective siVwf resulted in dose-dependent inhibition of up to 80% of both lung messenger RNA and plasma VWF protein in both mouse strains. In contrast, the allele-selective siVwf.B6 and siVwf.129S were shown to be effective in and selective solely for their corresponding mouse strain. To conclude, we showed efficient endothelial delivery of siRNAs that are highly effective in allele-selective inhibition of Vwf in mice, which constitutes an in vivo proof of principle of allele-selective VWF silencing as a therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA.
ORCID-Profile: Yvonne K Jongejan, Elisa Schrader Echeverri, Richard J Dirven, Kalina Paunovska, Noa A Linthorst, Annika de Jong, Bart J M van Vlijmen, James E Dahlman, Jeroen C J Eikenboom
Zitieren
APA
Jongejan, Y. K., Schrader Echeverri, E., Dirven, R. J., Paunovska, K., Linthorst, N. A., de Jong, A., Wellershoff, J. C., van der Gouw, K. D., van Vlijmen, B. J. M., Dahlman, J. E., & Eikenboom, J. C. J. (2023). Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo. Blood Advances. https://doi.org/10.1182/bloodadvances.2023010643
Vancouver
Jongejan YK, Schrader Echeverri E, Dirven RJ, Paunovska K, Linthorst NA, de Jong A, et al. Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo. Blood Advances. 2023. doi:10.1182/bloodadvances.2023010643
BibTeX
@article{Jongejan2023,
author = {Jongejan, Yvonne K and Schrader Echeverri, Elisa and Dirven, Richard J and Paunovska, Kalina and Linthorst, Noa A and de Jong, Annika and Wellershoff, Johannes C and van der Gouw, Kim D and van Vlijmen, Bart J M and Dahlman, James E and Eikenboom, Jeroen C J},
title = {Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo},
journal = {Blood Advances},
year = {2023},
doi = {10.1182/bloodadvances.2023010643}
}
EUVIMED